Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression
Manuela Terranova-Barberio, Maria Serena Roca, Andrea Ilaria Zotti, et al.
Oncotarget (2015) Vol. 7, Iss. 7, pp. 7715-7731
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Manuela Terranova-Barberio, Scott Thomas, Niwa Ali, et al.
Oncotarget (2017) Vol. 8, Iss. 69, pp. 114156-114172
Open Access | Times Cited: 153
Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer
Hayley Heers, Jennifer Stanislaw, John Harrelson, et al.
European Journal of Pharmacology (2018) Vol. 835, pp. 61-74
Closed Access | Times Cited: 85
New drugs are not enough‑drug repositioning in oncology: An update
Romina Armando, Diego Mengual G�mez, Daniel E. Gómez
International Journal of Oncology (2020)
Open Access | Times Cited: 81
Hidden pharmacological activities of valproic acid: A new insight
Dhirendra Kumar Singh, Sumeet Gupta, Inderjeet Verma, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 142, pp. 112021-112021
Open Access | Times Cited: 72
A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid
Ayesha Safdar, Fátima Ismail
Saudi Pharmaceutical Journal (2022) Vol. 31, Iss. 2, pp. 265-278
Open Access | Times Cited: 41
Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome
Yan Lou, Qian Wang, Jinqi Zheng, et al.
Chemical Research in Toxicology (2016) Vol. 29, Iss. 10, pp. 1591-1601
Closed Access | Times Cited: 67
Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents
Ana Matošević, Anita Bosak
Archives of Industrial Hygiene and Toxicology (2020) Vol. 71, Iss. 4, pp. 285-299
Open Access | Times Cited: 67
Epigenetic Modifiers in Immunotherapy: a Focus on Checkpoint Inhibitors
Manuela Terranova-Barberio, Scott Thomas, Pamela N. Münster
Immunotherapy (2016) Vol. 8, Iss. 6, pp. 705-719
Open Access | Times Cited: 66
Valproic Acid and Breast Cancer: State of the Art in 2021
Anna Wawruszak, Marta Hałasa, Estera Okoń, et al.
Cancers (2021) Vol. 13, Iss. 14, pp. 3409-3409
Open Access | Times Cited: 53
Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs
Diana Duarte, Armando Cardoso, Nuno Vale
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7408-7408
Open Access | Times Cited: 46
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
Maria Serena Roca, Tania Moccia, Federica Iannelli, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 31
Thymidine phosphorylase: A potential new target for treating cardiovascular disease
Wei Li, Hong Yue
Trends in Cardiovascular Medicine (2017) Vol. 28, Iss. 3, pp. 157-171
Open Access | Times Cited: 61
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
Rashmi R. Shah, Peter Stonier
Journal of Clinical Pharmacy and Therapeutics (2018) Vol. 44, Iss. 1, pp. 6-22
Open Access | Times Cited: 51
Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition
Federica Iannelli, Maria Serena Roca, Rita Lombardi, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 42
Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way
Wei Li, Hao Wu, Shiyao Sui, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 35
Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells
Diana Duarte, Alexandra Rêma, Irina Amorim, et al.
Biomolecules (2022) Vol. 12, Iss. 2, pp. 190-190
Open Access | Times Cited: 24
Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
Maria Serena Roca, Elena Di Gennaro, Alfredo Budillon
Journal of Clinical Medicine (2019) Vol. 8, Iss. 7, pp. 912-912
Open Access | Times Cited: 37
Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges
Katarzyna Lipska, Anna Gumieniczek, Agata Filip
Acta Pharmaceutica (2020) Vol. 70, Iss. 3, pp. 291-301
Open Access | Times Cited: 33
Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
Jianwei Feng, Xinyue Meng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Control of Redox Homeostasis by Short-Chain Fatty Acids: Implications for the Prevention and Treatment of Breast Cancer
Carmen González‐Bosch, Patricia A. Zunszain, Giovanni E. Mann
Pathogens (2023) Vol. 12, Iss. 3, pp. 486-486
Open Access | Times Cited: 12
Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications
Shilpi Sarkar, Dheepika Venkatesh, Thirukumaran Kandasamy, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 8
Open Access | Times Cited: 4
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
Manuela Terranova-Barberio, Biagio Pecori, Maria Serena Roca, et al.
Journal of Experimental & Clinical Cancer Research (2017) Vol. 36, Iss. 1
Open Access | Times Cited: 36
Effect of 5-aza-2'-deoxycytidine in comparison to valproic acid and trichostatin A on histone deacetylase 1, DNA methyltransferase 1, and CIP/KIP family (p21, p27, and p57) genes expression, cell growth inhibition, and apoptosis induction in colon cancer SW480 cell line
Fraidoon Kavoosi, Masumeh Sanaei
Advanced Biomedical Research (2019) Vol. 8, Iss. 1, pp. 52-52
Open Access | Times Cited: 35
Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
Tingting Lin, Qun Ren, Weimin Zuo, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 32
Prospects for repurposing CNS drugs for cancer treatment
Mohamed Abdelaleem, Hossam Ezzat, Muhammed Osama, et al.
Oncology Reviews (2019) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top